Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
3HP-2827 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
3HP-2827: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
TCC1727 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
TCC1727: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CTL(Shenzhen Geno-Immune Medical Institute) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
CTL(Shenzhen Geno-Immune Medical Institute): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CD123 targeted CAR-NK cells(Chongqing Precision Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
CD123 targeted CAR-NK cells(Chongqing Precision Biotech): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP.
8 min read
ION337 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
ION337: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical.
8 min read
AAV9-CLN6 gene therapy(Nationwide Children's Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
AAV9-CLN6 gene therapy(Nationwide Children's Hospital): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
8 min read
QLC1101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
QLC1101: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
TQB2922 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
TQB2922: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Dendritic Cells(Radboud University Medical Center) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
Dendritic Cells(Radboud University Medical Center): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
8 min read
SKY-GJB2 (Skylark Bio) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
SKY-GJB2 (Skylark Bio): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
68Ga-NODAGA-LM3 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
68Ga-NODAGA-LM3: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.